Technology
Choose a subcategory:
About Immunomedics Immunomedics is a New Jersey-based biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases.
Progress was made in preparing the Company's production facilities, including the Company's contract manufacturer, for various FDA inspections and additional preclinical studies were conducted assessing the potential use of Ampligen ( R), a
Dr. Laffer has served on the OXiGENE Board of Directors since 1998 and had served as Chair of the Audit Committee, the Chair of the Compensation Committee and a member of the Nominating and Governance Committee.
Clean Diesel Technologies is a cleantech company providing sustainable solutions to reduce emissions, increase energy efficiency and lower the carbon intensity of on- and off-road engine applications.
a leader in the discovery and development of antibody therapeutics, announced results demonstrating that a murine equivalent of XOMA 052, its novel, high-affinity antibody to interleukin-1 beta ( IL-1 beta), significantly reduced adverse co
These risks, including those related to inability to comply with NASDAQ's continued listing requirements; the declining and generally unstable nature of current economic conditions; the results of discovery research and pre-clinical testing
Other risks that may affect forward-looking information contained in this press release include the company's extremely limited capital resources, the possibility of being unable to obtain regulatory approval for Hedrin or its other product
Chelsea Therapeutics to Present at the ROTH 22nd Annual OC Growth Stock Conference on Wednesday, Mar
These risks and uncertainties include our need to raise operating capital, our history of losses, risks and costs of drug development, risk of regulatory approvals, our reliance on our lead drug candidates droxidopa and CH-4051, reliance on
For more information on Beacon Research, please visit http:// www. BeaconEquity. com Beacon Equity Disclosure DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT.
To read the entire report visit: http:// www.beaconequity. com/i/ BPAX See what investors are saying about BPAX at penny stock forum BeaconEquity. com is one of the industry's largest small-cap report providers.
To read the entire report visit: http:// www.stockpreacher. com/n/ GNBT See what investors are saying about GNBT at penny stock forum StockPreacher. com is a small-cap research and investment commentary provider.
Priorities for 2010- Report interim results from an 80 patient, Phase 2a trial of XOMA 052 in Type 2 diabetes with 60 patients on active drug and 20 patients on placebo- Conduct a 325 patient Phase 2b dose-ranging trial of XOMA 052 in Type